Molecular Partners Up in Trading Debut on Allergan Support
This article is for subscribers only.
Molecular Partners AG shares rose on the Swiss company’s trading debut, the second-biggest biotechnology offering in Europe since 2007, as Allergan Inc. supported the sale.
Molecular Partners put its listing on hold two weeks ago, citing a volatile stock market, and resumed book-building for the offer two days ago. Allergan, the Irvine, California-based drugmaker that funds development of Molecular Partners’ most advanced eye medicine, supported the IPO with an investment, according to the Swiss company.